Da de potentielle risici for menneskefostre under udvikling er ukendte, skal anvendelse af emtricitabin til kvinder i den fertile alder ledsages af brug af sikker kontraception.
Given that the potential risks to developing human foetuses are unknown, the use of emtricitabine in women of childbearing potential must be accompanied by the use of effective contraception.